Indication: For the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors
Pharmacology: Toremifene is an antineoplastic hormonal agent primarily used in the treatment of advanced breast cancer. Toremifene is a nonsteroidal agent that has demonstrated potent antiestrogenic properties in animal test systems. The antiestrogenic effects may be related to its ability to compete with estrogen for binding sites in target tissues such as breast. Toremifene inhibits the induction of rat mammary carcinoma induced by dimethylbenzanthracene (DMBA) and causes the regression of already established DMBA-induced tumors. In this rat model, Toremifene appears to exert its antitumor effects by binding the estrogen receptors. In cytosols derived from human breast adenocarcinomas, Toremifene competes with estradiol for estrogen receptor protein.
Mechanism Of Action: Toremifene is a nonsteroidal triphenylethylene derivative. Toremifene binds to estrogen receptors and may exert estrogenic, antiestrogenic, or both activities, depending upon the duration of treatment, animal species, gender, target organ, or endpoint selected. The antitumor effect of toremifene in breast cancer is believed to be mainly due to its antiestrogenic effects, ie, its ability to compete with estrogen for binding sites in the cancer, blocking the growth-stimulating effects of estrogen in the tumor.
Drug Category: Antineoplastic Agents; Selective Estrogen Receptor Modulators; ATC:L02BA02
Interactions:
DrugBank: Interactions for Toremifene
Interactions for Toremifene:
Drugs that decrease renal calcium excretion, eg, thiazide diuretics, may increase the risk of hypercalcemia in
patients receiving FARESTON. There is a known interaction between antiestrogenic compounds of the triphenylethylene
derivative class and coumarin-type anticoagulants (eg, warfarin), leading to an increased prothrombin time. When
concomitant use of anticoagulants with FARESTON is necessary, careful monitoring of the prothrombin time is
recommended.
Cytochrome P450 3A4 enzyme inducers, such as phenobarbital, phenytoin, and carbamazepine increase the rate of
toremifene metabolism, lowering the steady-state concentration in serum. Metabolism of toremifene may be inhibited by
drugs known to inhibit the CYP3A4-6 enzymes. Examples of such drugs are ketoconazole and similar antimycotics as well
as erythromycin and similar macrolides. This interaction has not been studied and its clinical relevance is
uncertain.
Chemical IUPAC Name: 2-[4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy]-N,N-dimethyl-ethanamine
Chemical Formula: C26H28ClNO
Half Life: 5 days
Drug Type: Approved Drug
# Accession No: APRD00391
CAS Registry Number: 89778-26-7
Toremifene News (When available)
Biotechs find themselves more coveted15 Jan 2006 Philadelphia Inquirer, GTx expects to complete the final phase of testing for regulatory approval of its Acapodene prostate-cancer drug by the end of next year. ...
GTx Reports Positive Phase III Trial Interim Analysis ResultsDec 15, 2005 PR Newswire (press release), ...therapy (ADT) experienced highly statistically significant increases in bone mineral density (BMD) after one year of treatment with ACAPODENE(R) (toremifene ...
GTX stock on rise following positive trial resultsDec 15, 2005 Memphis Business Journal, Preliminary findings in a pivotal Phase III clinical study of the drug Acapodene shows that patients being treated for prostate cancer are experiencing up to ...
GTx says drug shown to strengthen bonesDec 15, 2005 BusinessWeek ...a biotech company specializing in men's health products, said Thursday that data from a late-stage clinical trial showed that its Acapodene treatment increased ...
Daily briefingDec 16, 2005 commercialappeal.com (subscription), Memphis bioscience company, GTx said Thursday data from a late-stage clinical trial showed its Acapodene treatment increased bone mineral density in men using ...
Home
Copyright phasechange.org 2006.
All Rights Reserved.
